ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CLDN6/CD3 Bispecific Antibody XmAb541

Its studies are mostly in Ovarian Neoplasms, led by Xencor.

Furthest: phase 1, since Feb 16, 20242 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Xencor22 open or runningphase 1since Feb 16, 2024Feb 16, 2024Dec 2027phase 1 · NCT06276491

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 16, 2024First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT06276491 · 282 planned · United States, Belgium, Denmark and more
  2. May 11, 2026Phase 1 study in Ovarian NeoplasmsNCT07593092 · 90 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 1 study in Ovarian NeoplasmsNCT06276491
  2. Dec 2028Primary completion: phase 1 study in Ovarian NeoplasmsNCT07593092

TargetBeta

CD3E →CLDN6 →read by rule
“A bispecific antibody directed against both the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6) and the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455ruleBeOne Medicinesphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07593092Ovarian Neoplasms · United States1RecruitingDec 202890
NCT06276491Ovarian Neoplasms · United States, Belgium, Denmark and more1RecruitingDec 2027282

How it is read

Names in the registry

  • “XmAb541”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.